Binds Drug, Hapten, Hapten-carrier Complex, Or Specifically-identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 530/389.8)
-
Publication number: 20130287795Abstract: The present invention relates to a novel antibody against ephrin B2 and its use to detect the protein and as a medicament for inhibiting angiogenesis and lymphangiogenesis in the treatment of diseases in which these processes are implicated, for example, cancer.Type: ApplicationFiled: September 20, 2011Publication date: October 31, 2013Applicant: FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICASInventors: Jorge Luis Martinez Torrecuadrada, Maria Angeles Abengozar Infantes
-
Publication number: 20130289248Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.Type: ApplicationFiled: June 13, 2013Publication date: October 31, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne VAN RYN, John Edward PARK, Norbert HAUEL, Ulrich KUNZ, Tobias LITZENBURGER, Keith CANADA, Sanjaya SINGH, Alisa WATERMAN
-
Publication number: 20130280740Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: ApplicationFiled: June 14, 2013Publication date: October 24, 2013Inventors: Murthy V.S.N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
-
Patent number: 8563700Abstract: The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone or the administration of one or more of the drug(s) without the conjugate. The present invention is also directed to compositions comprising at least one conjugate and at one or more of chemotherapeutic agent and to methods of treating cancer using at least one conjugate and at least one or more of chemotherapeutic agent(s). The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of one or more chemotherapeutic agent(s) and at least one conjugate. In each case, such combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the anticancer agent(s) alone.Type: GrantFiled: June 16, 2009Date of Patent: October 22, 2013Assignee: ImmunoGen, Inc.Inventors: Robert J. Lutz, Kathleen R. Whiteman
-
Publication number: 20130273545Abstract: This invention relates to methods of diagnosing Alzheimer's disease and methods of screening for compounds for the treatment or prevention of Alzheimer's disease. The methods are based upon newly discovered differences in protein phosphatase 2A (PP2A) function and related molecular events in Alzheimer's disease cells compared to control cells. In one embodiment, differences in basal PP2A gene expression in Alzheimer's cells are compared to controls. In another embodiment differences in PP2A protein and enzyme activity are compared in test and control cells. In another embodiment differences in response to substances that inhibit PP2A function are compared. Still another embodiment detects differences in the subcellular distribution of phosphorylated Erk1/2, a substrate of PP2A, in normal and Alzheimer's disease cells.Type: ApplicationFiled: February 15, 2013Publication date: October 17, 2013Inventors: Wei-Qin Zhao, Daniel L. Alkon
-
Publication number: 20130274449Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.Type: ApplicationFiled: March 13, 2013Publication date: October 17, 2013Inventors: Ernest S. SMITH, Terrence Lee Fisher
-
Publication number: 20130273581Abstract: The invention relates to haptens, immunogens and secondary immunoreactive agents, to the use thereof for producing wide-spectrum antibodies against quinolone-type antibiotics, to the application thereof to immunochemical analysis techniques, and to a kit enabling the detection of said antibiotics in biological samples from food products of animal origin.Type: ApplicationFiled: November 21, 2011Publication date: October 17, 2013Inventors: Maria Pilar Marco Colas, Francisco José Sánchez Baeza, Daniel González Pinacho
-
Publication number: 20130273051Abstract: In some aspects, general methods to develop highly selective inhibitory antibodies towards members of the metzincin superfamily of metalloproteases and their application for therapeutic and diagnostic uses are provided. The methods employ the generation of novel catalytic cleft-directed antibodies with neutralising selectivity for the targeted metzincin metalloendoproteinase employing immunogenic peptides encompassing the consensus metzincin catalytic motif. In some aspects, methods include the employment of such antibodies for therapeutic purposes and/or as an inhibitory component of an assay system allowing discrimination between the activity of the targeted metzincin and other endogenous metzincins within a biological sample. Such assays may be employed for diagnostic or prognostic purposes.Type: ApplicationFiled: October 1, 2011Publication date: October 17, 2013Inventors: Salman Rahman, Yatin Patel
-
Publication number: 20130273072Abstract: The present invention nucleic acids encoding novel antibodies and functional fragments thereof specific for CD38. Such antibodies are useful for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: ApplicationFiled: June 14, 2013Publication date: October 17, 2013Inventors: Michael Tesar, Ute Jäger
-
Publication number: 20130273076Abstract: The invention provides methods of screening a compound that can increase spine/excitatory synapse formation and/or numbers. The compound is identified by contacting Ephexin5 with a test compound and selecting the compounds that inhibit Rho GEF activity of Ephexin5. Additionally, the invention also provides methods for increasing spine/excitatory synapse formation and/or numbers by contacting a neuron with an Ephexin5 inhibitor.Type: ApplicationFiled: October 25, 2011Publication date: October 17, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: John Salogiannis, Michael E. Greenberg, Seth S. Margolis
-
Publication number: 20130267687Abstract: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind to an antigen which is the same as that bound by an antibody which is produced by the hybridoma cell lines CUB1, CUB2, CUB3 and CUB4, which were deposited in the DSMZ under the numbers DSM ACC2569, DSM ACC2566 and DSM ACC2565, on Aug. 14, 2002, and DSM ACC2551, on Jul. 12, 2002.Type: ApplicationFiled: April 23, 2013Publication date: October 10, 2013Applicant: HOFFMAN-LA ROCHE INC.Inventors: HANS-JOERG BUEHRING, REINER LAMMERS, SELIM KUCI, TIM CONZE
-
Publication number: 20130266517Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: ApplicationFiled: January 25, 2013Publication date: October 10, 2013Inventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20130267689Abstract: Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.Type: ApplicationFiled: March 22, 2013Publication date: October 10, 2013Inventors: John Latham, David G. Winkler
-
Publication number: 20130266584Abstract: The invention features the treatment of gastrointestinal disorders associated with an innate immune response tiggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.Type: ApplicationFiled: April 29, 2011Publication date: October 10, 2013Inventors: Detlef Schuppan, Yvonne Junker, Towia Libermann, Simon T. Dillon
-
Publication number: 20130252347Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: ApplicationFiled: March 12, 2013Publication date: September 26, 2013Applicant: Hansa Medical ABInventors: Lars Bjorck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Akesson
-
Publication number: 20130252307Abstract: The invention provides a method for increasing the stability and/or activity of a polypeptide at low pH and/or elevated temperatures. The invention further provides a method for increasing the melting temperature of a polypeptide. Also provided are paleoenzymologically reconstructed thioredoxin polypeptides having activity at higher temperatures and/or lower pH than extant thioredoxin polypepetides, as well as paleoenzymologically reconstructed thioredoxin polypeptides having higher melting temperatures than extant thioredoxin polypepetides.Type: ApplicationFiled: July 15, 2011Publication date: September 26, 2013Applicant: GEORGIA TECH RESEARCH CORPORATIONInventors: Julio M. Fernandez, Raul Perez-Jimenez, Eric Gaucher, Pallav Kosuri
-
Publication number: 20130252255Abstract: Provided are a bladder cancer diagnosis composition containing APE1/Ref-1, a bladder cancer diagnostic kit containing an antibody which specifically binds to the APE1/Ref-1, and a method of measuring APE1/Ref-1 concentration in biological samples through an antigen-antibody binding reaction using the antibody which specifically binds to the APE1/Ref-1. According to the invention, the APE1/Ref-1 protein concentration in serum of bladder cancer patients is significantly higher than in healthy subjects, and more particularly, it significantly increases in the serum of patients with stage 2 or later bladder cancer.Type: ApplicationFiled: December 8, 2011Publication date: September 26, 2013Applicant: THE INDUSTRY & ACADEMY COOPERARATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)Inventors: Byeong-Hwa Jeon, Sung-A Choi, Ju-Hyun Shin
-
Patent number: 8541554Abstract: An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays.Type: GrantFiled: December 29, 2010Date of Patent: September 24, 2013Assignee: Abbott LaboratoriesInventors: Frank C. Grenier, Ryan F. Workman, Hina Syed, Salman Ali
-
Publication number: 20130245237Abstract: The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.Type: ApplicationFiled: April 4, 2013Publication date: September 19, 2013Applicant: Cell Signaling Technology, Inc.Inventors: John Edward Rush, II, Jing Li, Ailan Guo
-
Publication number: 20130243795Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: JANSSEN BIOTECH, INC.Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
-
Publication number: 20130245230Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.Type: ApplicationFiled: March 6, 2013Publication date: September 19, 2013Applicant: The Scripps Research InstituteInventors: Alexander Dieters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
-
Publication number: 20130243789Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins.Type: ApplicationFiled: January 11, 2013Publication date: September 19, 2013Applicant: Abbott LaboratoriesInventors: Gerald R. Carson, Jochen G. Salfeld, Dean A. Regier, Jijie Gu, Wendy Gion, Yune Z. Kunes
-
Publication number: 20130236478Abstract: Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 ?, and methods of using the same.Type: ApplicationFiled: December 10, 2012Publication date: September 12, 2013Applicant: Instituto Nacional De Psiquiatria Ramon De La Fuente MunizInventors: Benito Anton PALMA, Philippe Leff GELMAN
-
Publication number: 20130236398Abstract: Antibodies and antibody fragments that selectively bind to nanoparticles are provided herein.Type: ApplicationFiled: March 12, 2012Publication date: September 12, 2013Applicant: Empire Technology Development LLCInventor: Michael Keoni Manion
-
Publication number: 20130230505Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: ApplicationFiled: May 26, 2011Publication date: September 5, 2013Applicants: Pangu BioPharma Limited, aTyr Pharma Inc.Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20130224225Abstract: An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.Type: ApplicationFiled: April 29, 2013Publication date: August 29, 2013Applicant: Yeda Research and Development Co., Ltd.Inventor: Yeda Research and Development Co., Ltd.
-
Publication number: 20130224882Abstract: The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity.Type: ApplicationFiled: February 22, 2013Publication date: August 29, 2013Applicant: Randox Laboratories LimitedInventor: Randox Laboratories Limited
-
Publication number: 20130217036Abstract: The present invention relates in particular to methods of detecting predisposition to or diagnosis and/or prognosis of Charcot-Marie-Tooth (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers, which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes, assessing the responsiveness to the treatments and the efficacy of treatments in subjects having CMT or a related disorder.Type: ApplicationFiled: November 19, 2010Publication date: August 22, 2013Applicant: PharnextInventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
-
Publication number: 20130216554Abstract: Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.Type: ApplicationFiled: May 12, 2011Publication date: August 22, 2013Inventors: Chutima Talchai, Domenico Accili
-
Publication number: 20130209491Abstract: A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with: (i) a synthetic zinc mimicry compound having structural and electronic properties similar to a catalytic domain of the metalloenzyme; and (ii) the metalloenzyme, Antibodies generated by this method are also disclosed as well as uses thereof.Type: ApplicationFiled: October 27, 2011Publication date: August 15, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Irit Sagi, Netta Sela-Paswell, Moran Grossman
-
Publication number: 20130210167Abstract: The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones.Type: ApplicationFiled: February 8, 2013Publication date: August 15, 2013Applicant: RANDOX LABORATORIES LIMITEDInventor: Randox Laboratories Limited
-
Publication number: 20130211052Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.Type: ApplicationFiled: March 28, 2013Publication date: August 15, 2013Applicant: Saladax Biomedical Inc.Inventor: Saladax Biomedical Inc.
-
Publication number: 20130203076Abstract: Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP.Type: ApplicationFiled: February 2, 2012Publication date: August 8, 2013Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventor: Bhalchandra Lele
-
Publication number: 20130203065Abstract: A method for performing homogeneous immunoassay formats with electrochemical detection in solution includes combining two different conjugates as reagents with a sample or a sample/buffer mixture, one conjugate including a redox marker and an analyte molecule and the second conjugate including an anti-redox marker antibody or a specifically binding fragment thereof and a molecule specifically binding the analyte.Type: ApplicationFiled: May 25, 2011Publication date: August 8, 2013Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Julia Ettlinger, Nenad Gajovic-Eichelmann, Burkhard Micheel, Gudrun Scharte, Jörg Schenk
-
Publication number: 20130197514Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.Type: ApplicationFiled: December 18, 2012Publication date: August 1, 2013Applicant: University of Massachusetts Medical SchoolInventor: University o Massachusetts Medical School
-
Publication number: 20130196354Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: ApplicationFiled: August 14, 2012Publication date: August 1, 2013Applicant: RANDOX LABORATORIES LIMITEDInventors: Stephen Peter Fitzgerald, Paul John Innocenzi, Elouard Benchikh, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20130190190Abstract: Molecular biomarkers as indicators of responses to steroids, drug targets, predictors of steroid responses and identification of drugs for modulating intraocular pressure. Kits and methods of identifying and distinguishing between steroid responders and non-responders.Type: ApplicationFiled: December 4, 2008Publication date: July 25, 2013Inventors: Stephen G. Schwartz, Elizabeth M. Fini
-
Publication number: 20130189710Abstract: An antibody, which specifically recognizes adducts between pyrrole and cellular macromolecules. Such adducts are likely to occur in mammals suffering an incident of pyrrolizidine alkaloid poisoning. The antibody can be produced using a synthetic immunogen conjugated with a pyrrole as a hapten and it can be used, for example in an assay kit and/or by itself, as a novel means for detecting or diagnosing pyrrolizidine alkaloid poisoning both clinics and research laboratories.Type: ApplicationFiled: January 20, 2012Publication date: July 25, 2013Inventors: Ge Lin, Jiang Zheng, Na Li
-
Publication number: 20130189281Abstract: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.Type: ApplicationFiled: September 27, 2012Publication date: July 25, 2013Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20130189243Abstract: The present invention provides methods and compositions for the diagnosis of acute ischemic stroke. The invention further provides methods and compositions for distinguishing acute ischemic stroke from other forms of stroke and TIAs and “stroke mimic” events. Moreover, methods and compositions are provided to facilitate the treatment of acute ischemic stroke patients.Type: ApplicationFiled: February 22, 2011Publication date: July 25, 2013Inventors: Taura L. Barr, Maria Del Mar Matarin, Steven Jay Warach, Andrew Barry Singleton, Yvette P. Conley
-
Publication number: 20130183693Abstract: A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.Type: ApplicationFiled: March 13, 2013Publication date: July 18, 2013Inventors: Prasad DEVARAJAN, Jonathan M. Barasch
-
Publication number: 20130183320Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.Type: ApplicationFiled: January 18, 2013Publication date: July 18, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Patent number: 8481690Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: GrantFiled: July 30, 2009Date of Patent: July 9, 2013Assignee: IDEXX Laboratories, Inc.Inventors: Yerramilli V. S. N. Murthy, Mahalakshmi Padmanabhan, Michael Atkinson, Kwok Kam Yeung
-
Publication number: 20130171661Abstract: A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.Type: ApplicationFiled: January 3, 2013Publication date: July 4, 2013Applicant: MEDICAL RESEARCH COUNCILInventor: MEDICAL RESEARCH COUNCIL
-
Publication number: 20130172204Abstract: The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma.Type: ApplicationFiled: April 13, 2011Publication date: July 4, 2013Applicant: M-LAB AGInventors: Franz Grus, Nils Boehm, Norbert Pfeiffer, Katharina Bell
-
Publication number: 20130165338Abstract: The invention relates to a method for determining the temporal phase of acute kidney injury, comprising obtaining a test sample from a subject and measuring the expression level of at least one biomarker selected from the group comprising Chac1, Birc5 and Angpt17. The invention also relates to a method for determining the early early phase, the late early phase, the severity and/or timing of acute kidney injury via analysis of the biomarkers Chac1, Birc5 and/or Angptl7, in addition to a test kit for carrying out said methods and antibodies directed against Chac1, Birc5 or Angptl7.Type: ApplicationFiled: June 17, 2011Publication date: June 27, 2013Applicant: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Kai Schmidt-Ott, Anne Wuebken
-
Publication number: 20130158237Abstract: Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.Type: ApplicationFiled: November 19, 2012Publication date: June 20, 2013Applicant: PANASONIC CORPORATIONInventor: PANASONIC CORPORATION
-
Publication number: 20130157295Abstract: The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: or a prodrug or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: January 28, 2013Publication date: June 20, 2013Applicant: NATURON PHARMACEUTICALS, INC.Inventor: Naturon Pharmaceuticals, Inc.
-
Publication number: 20130142813Abstract: In order to identify a factor demonstrating a repellent effect on axon extension of a neuron, lysophosphatidylglucoside (LPG) has been found to have an activity as a chemorepellent effect on axon guidance of a DRG sensory neuron specific to a neuron expressing TrkA, an NGF receptor. In addition, it has been found out that suppressing the function of LPG makes it possible to suppress a repellent effect of LPG on axon extension of a neuron expressing TrkA. A molecule capable of suppressing the function of LPG can be a composition promoting repairing of a neural circuit in neuronal damages and the like.Type: ApplicationFiled: July 7, 2011Publication date: June 6, 2013Applicant: RIKENInventors: Yoshio Hirabayashi, Hiroyuki Kamiguchi, Kunihiro Ohta, Akiho Nakamura
-
Publication number: 20130143827Abstract: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.Type: ApplicationFiled: January 28, 2013Publication date: June 6, 2013Applicant: Wyeth LLCInventor: Wyeth LLC